Halozyme Therapeutics vs Repligen
HALO and RGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HALO and RGEN compare
Halozyme Therapeutics is the larger company, worth 1.5 times as much as Repligen ($14.9B against $10.0B).
Halozyme Therapeutics grew revenue faster over the last twelve months (41.2% versus 13.8% for Repligen).
Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −1.5% at Repligen.
Halozyme Therapeutics scores higher on the StockData Score (13 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HALO | RGEN |
|---|---|---|
| Size and price | ||
| Market cap | $14.9B | $10.0B |
| Share price | $130.91 | $176.94 |
| Change, 1 year | 101% | 19.2% |
| Change, 5 years | 222% | −33.7% |
| Beta (5Y) | 0.71 | 1.50 |
| Employees | 423 | 2,000 |
| StockData Score | ||
| Total score | 13 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 5 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 38.6× | – |
| P/S | 8.9× (better) | 12.4× |
| P/B | 104× | 4.8× (better) |
| EV/EBITDA | 27.5× (better) | 94.9× |
| P/FCF | 18.4× (better) | 93.6× |
| PEG | 1.83 | – |
| FCF yield | 5.4% (better) | 1.1% |
| Fair value | $69.98 | $79.82 |
| Margin of safety | −87.1% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 41.2% (better) | 13.8% |
| Revenue growth, 5Y average | 39.2% (better) | 15.0% |
| Net income growth (TTM) | −25.8% (better) | −779% |
| EPS growth (TTM) | −22.4% | – |
| EPS growth, 5Y average | 23.0% (better) | −5.0% |
| Profitability | ||
| Gross margin | 82.4% (better) | 53.5% |
| Operating margin | 35.9% (better) | 2.3% |
| Net margin | 24.9% (better) | −1.5% |
| FCF margin | 48.5% (better) | 13.2% |
| Return on equity | 174% (better) | −0.57% |
| Return on invested capital | 21.7% (better) | 0.71% |
| Financial health | ||
| Debt / equity | 14.95 | – |
| Net debt / EBITDA | 3.24 | – |
| Interest coverage | 29.4× (better) | 0.8× |
| Current ratio | 2.71 | 9.88 (better) |
| Altman Z-score | 5.43 | 8.14 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 117% |
| Held by insiders | 1.3% | 0.67% |
| Insider net buying, 12 months | −$41.2M | −$14.2M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 13.7% | 13.5% |
Go deeper
- HALO stock overview
- HALO income statement
- HALO valuation and score
- RGEN stock overview
- RGEN income statement
- RGEN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.